CONSOLIDATED FINANCIAL HIGHLIGHTS

Q1 FY 2026-27

Three months ended 30 September 2026

Renata PLC and its subsidiaries (consolidated)

RENATA PLC

Business Highlights Presentation · 01 November 2026




Disclaimer

This presentation is intended for the relevant stakeholders having reasonable knowledge of business and economic activities to facilitate diligent review and analysis of the information.

The information contained in this presentation regarding the past prices or returns of relevant investments should not be relied upon as a guide to future investment appraisals.

This presentation does not constitute an offer of securities or an invitation to underwrite, subscribe or acquire securities in Renata PLC.

This document presents consolidated financial information for Renata PLC and its Subsidiaries, unless stated otherwise.



Contents

01 **Overview** — Renata at a glance and the period's headline figures — 4

02 **Revenue** — Revenue by segment, its growth and the revenue mix — 6

03 **Profitability** — Performance metrics, margins, revenue to profit and LTM EBITDA — 7

04 **Cost drivers** — The drivers of cost and the finance cost bridge — 10

05 **Shareholder value and key items from financial position** — EPS, NOCFPS and NAVPS; trend of the key items from financial position — 12

06 **Other highlights** — R&D, manufacturing efficiency, export and market penetration, the interest rate swap — 14

07 **Annexure** — Annexure A (quarter 1 and year to date) — 16



Renata at a Glance: Q1 FY 2026-27

Revenue up by 11.4% and profit up by 37.2%; solo profit up by 44.7%.

11.4% (Solo 11.6%)

Revenue growth primarily driven by volume

37.2% (Solo 44.7%)

Profit growth driven by sourcing, operating and financing efficiency

35.2%

Net financing cost reduced by BDT 150m

100

Bio-equivalent product portfolio to date

77


International markets presence to date across multiple continents

BDT 365m

Incremental capital investments




Financial Highlights Q1 FY 2026-27




BDT 12.60bn

Revenue




BDT 8.18bn

LTM EBITDA




BDT 1.02bn

Profit for the Period




BDT 8.87

Earnings Per Share



BDT 21.98

Net Operating Cash Flow Per Share




BDT 339.31

Net Asset Value Per Share




Revenue Growth

Revenue up by 11.4% to BDT 12.60bn; export added the most, BDT 404m (31% of the growth).



*Revenue from export of pharmaceutical products includes subsidiaries' revenue.

Revenue Mix (Q1 FY 2026-27)




RENATA PLC

Other Performance Metrics

Profit rose by 37.2% to BDT 1.02bn and EBITDA +5.1%; cost of materials +13.0%, SDMA +11.9%, net finance costs -35.2%.


Cost of Materials

BDT million




Factory Overhead

BDT million




SDMA Expenses

BDT million




Net Finance Costs

BDT million




EBITDA

BDT million



Profit for the Period

BDT million




RENATA PLC

Margin Comparison: Q1 FY'27 vs Q1 FY'26

Net profit margin 8.1% against 6.6%; the LTM EBITDA margin gained most (+2.8pp).

% of revenue · Q1 FY'27 against Q1 FY'26 · EBITDA for the last twelve months to each quarter-end




	CHANGE	WHAT MOVED THE MARGIN
Gross margin	▲ 0.5pp	Cost of sales +10.5% against revenue +11.4%: revenue grew faster than cost of sales.
LTM EBITDA margin	▲ 2.8pp	LTM EBITDA +29.1% against LTM revenue +7.9%: the last twelve months to 30 Sep'26 against those of 30 Sep'25.
NPAT margin	▲ 1.5pp	Profit +37.2% against revenue +11.4%, cost of sales +10.5%, SDMA +11.9%, net finance costs -35.2%.

RENATA PLC

LTM EBITDA Journey

LTM EBITDA rose by +29.1% to BDT 8.18bn at 30 Sep'26 compared to LTM EBITDA at 30 Sep'25.

BDT million · EBITDA for the last twelve months to each quarter-end, 30 Sep'25 to 30 Sep'26



Profit after tax	2,368	2,536	2,731	3,643	3,919
Interest	1,854	1,837	1,701	1,431	1,299
Tax	297	362	447	760	825
Depreciation & amortization	1,778	1,862	1,950	2,036	1,922
Other adjustments	38	75	82	215	215

RENATA PLC

Factors Influencing the Achievement of Excellence

Following are the Q1 FY'27 vs Q1 FY'26 variances of the cost pools of FOH and SDMA in line with annual presentation.


Key Drivers	Q1 2026-27
Factory overhead (FOH)	
Increase in people costs reflecting annual salary increments and upgradation of employment status for temporary workforce	▲ 6.1%
Decrease in depreciation expenses following a change in the depreciation method for plant & machinery, better reflecting the pattern of consumption of the assets' future economic benefits	▼ 31.3%
Increased travelling and conveyance expenses due to higher operational movements and production-related activities	▲ 6.4%
Increase in energy costs due to multiple price adjustments, mainly for higher diesel prices and industrial electricity tariffs	▲ 27.1%
Increased supplies and consumables expenses in line with the expanded production volume	▲ 1.2%
Increase in repair & maintenance expenses due to higher preventive maintenance activities and breakdown-related repairs	▲ 11.6%
Administrative, selling, marketing and distribution expenses (SDMA)	
Increase in people costs driven by inflation-proof annual increments	▲ 6.8%
Decreased travelling and conveyance expenses underpinned by optimized field activities	▼ 0.2%
Increase in distribution expenses driven by higher sales volumes and inflationary pressure on fuel and logistics costs	▲ 9.4%
Increased depreciation expenses due to some major capital work-in-progress projects capitalization during FY 2025-26	▲ 11.9%
Increase in selling and marketing expenses driven by expanded brand investment and market-development initiatives	▲ 10.0%
Increased legal and professional expenses associated with corporate compliance and advisory services	▲ 29.7%



Finance Cost Bridge: Q1 FY'27

Net finance cost excluding exchange fell 30.4% to BDT 280m; interest before capitalization dropped by 38.6%.

BDT million · Q1 FY'27



NET FINANCE COST EXCL. FX


BDT 280m

▼ 30.4% vs Q1 FY'26

OF REVENUE

2.2%

−1.3pp vs Q1 FY'26




RENATA PLC

EPS, NOCFPS and NAVPS

EPS rose by 37.2% to BDT 8.87.


Earnings Per Share

BDT



Net Operating Cash Flow Per Share


BDT



NAV Per Share

BDT






PPE, Inventories, Retained Earnings and Debt

PPE grew by 1.44x and debt grew by 1.67x in 4.25 years.

Property, Plant & Equipment

BDT million


1.44x in 4.25 years, adding BDT 11.50bn for capacity enhancement



Inventories

BDT million


1.49x in 4.25 years, adding BDT 4.13bn for increased demand



Retained Earnings

BDT million


Increased by BDT 9.36bn in 4.25 years



Debt

BDT million

Increased by BDT 5.94bn in 4.25 years for PPE and WC



4.25 YEARS' CHANGE (BDT MILLION)

Property, Plant & Equipment **+11,500**

1.44x since 30 Jun'22; CAGR +8.9%.

Inventories **+4,129**

1.49x since 30 Jun'22; CAGR +9.8%.

Retained Earnings **+9,358**

1.33x since 30 Jun'22; CAGR +7.0%.

Debt **+5,938**

1.67x since 30 Jun'22; CAGR +12.8%.

RENATA PLC



Other Highlights



RENATA PLC

Other Highlights



R&D and Product Development

Emphasizes R&D and innovation, leveraging 100 bioequivalent products to strengthen its pipeline and broaden international market access.



Manufacturing Efficiency

Prioritizes productivity through resource optimization, yield analysis, Overall Equipment Effectiveness and throughput KPIs to improve equipment utilization, output, and efficiency.



Export and Market Penetration


UK MHRA approvals for Empagliflozin and Sertraline, and first Portugal shipment during the first quarter of FY 2026-27.



Interest Rate Swap

The Company entered into two interest rate swaps with Standard Chartered Bank for USD 15 million each, effective July 15, 2026, mitigating SOFR exposure and financing costs.

RENATA PLC



Annexure

RENATA PLC

Annexure A

Renata PLC (Consolidated)
Analytical data for quarter 1 and year to date
Amounts are in million BDT

Particulars	**Quarter 1 and Year to Date (Three Months)**			
	FY 2026-27/Sep'26	**FY 2025-26/Sep'25**	**Variance**	**%**
Revenue				
Pharmaceuticals	9,913	9,127	786	8.6%
Local	8,821	8,440	381	4.5%
Export	1,092	688	404	58.8%
Animal health	1,966	1,781	185	10.4%
Contract manufacturing	646	320	326	101.7%
Consumer & agro	78	80	(2)	(2.7%)
Total revenue	**12,603**	**11,308**	**1,294**	**11.4%**
Cost of sales	**6,936**	**6,278**	**658**	**10.5%**
Cost of materials	4,719	4,175	544	13.0%
Factory overhead	2,216	2,103	113	5.4%
Gross profit	**5,667**	**5,030**	**637**	**12.7%**
GP margin	45.0%	44.5%	0.5%	1.1%
Administrative expenses	661	551	109	19.9%
Selling, marketing and distribution expenses	3,419	3,093	326	10.5%
Operating profit	**1,588**	**1,386**	**201**	**14.5%**
EBITDA	1,961	1,866	95	5.1%
Net finance costs	275	425	(150)	(35.2%)
Profit for the Year	**1,018**	**742**	**276**	**37.2%**
Earning per share (in BDT)	8.87	6.47	2.41	37.2%
Net asset value per share (in BDT)	339.31	312.01	27.30	8.7%
Net operating cash flow per share (in BDT)	21.98	12.62	9.36	74.2%
Capex	365	1,041	(676)	(64.9%)
Financial position	**30 Sep'26**	**30 Jun'26**	**Variance**	**%**
Total assets	64,118	61,677	2,420	3.9%
Shareholders' equity	42,167	41,007	1,142	2.8%
Total liabilities	21,951	20,671	1,277	6.2%

RENATA PLC



Thank You



RENATA PLC